Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 63Colorectal Neoplasms 30Biliary Tract Neoplasms 29Cholangiocarcinoma 27Pancreatic Neoplasms 26Liver Neoplasms 18Stomach Neoplasms 13Esophageal Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 10Gallbladder Neoplasms 9Adenocarcinoma Of Esophagus 9Neoplasm Metastasis 8Esophageal Squamous Cell Carcinoma 8Ovarian Neoplasms 7Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 6Carcinoma, Renal Cell 6Carcinoma 6Bile Duct Neoplasms 6Triple Negative Breast Neoplasms 5Rectal Neoplasms 5Prostatic Neoplasms 5Colonic Neoplasms 5Uterine Cervical Neoplasms 4Lung Neoplasms 4Diabetes Mellitus, Insulin-Dependent, 12 4Adenocarcinoma 4Neoplasms 3

Interventions

Ultrasonography 2Tomography, X-Ray Computed 2Colonoscopy 2Blood Specimen Collection 2tremelimumab 1peginterferon alfa-2a 1lenvatinib 1hepatitis C immune globulin, human 1fluoromisonidazole 1epigallocatechin gallate 1durvalumab 1babao dan 1Weights and Measures 1Vitamin B 6 1Urination 1Tomography 1Tidal Volume 1Tenofovir 1Surgical Procedures, Operative 1Standard of Care 1Shadowing Technique, Histology 1Radiomics 1Propranolol 1Probiotics 1Preoperative Exercise 1Positron-Emission Tomography 1Portasystemic Shunt, Transjugular Intrahepatic 1Population Groups 1Plasmapheresis 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Cirrhosis × durvalumab × Gastrointestinal × Clear all
NCT06526104 2026-01-06

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

The University of Texas Health Science Center at San Antonio

Phase 2 Recruiting
32 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡